Article

Ophthalmic viscosurgical device recalled by FDA after reports of toxic anterior segment syndrome

The FDA has recalled one lot of an ophthalmic viscosurgical device ([OVD] Healon D, Advanced Medical Optics [AMO]) following a voluntary recall by the manufacturer. The lot number, UD30654, is displayed on the side panel of each unit.

Key Points

Rockville, MD-The FDA has recalled one lot of an ophthalmic viscosurgical device ([OVD] Healon D, Advanced Medical Optics [AMO]) following a voluntary recall by the manufacturer. The lot number, UD30654, is displayed on the side panel of each unit.

AMO voluntarily recalled all 4,439 units of the lot Oct. 30 after receiving complaints of inflammation after eye surgery, including toxic anterior segment syndrome (TASS). At that time, the company informed customers of the lot number and nature of adverse event reports and included a fax reply form for communication with the firm. As of Dec. 3, however, AMO had retrieved only 964 units of the 1,450 that had been distributed in the United States, according to the FDA.

AMO received 66 adverse event reports associated with the recalled product. Tests of the lot revealed elevated levels of endotoxin. FDA spokeswoman Siobhan DeLancey said the FDA characterizes the action as a Class I recall because the lot poses a "significant potential for harm to human health." The delayed classification merely restates the company's voluntary recall, she said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.